Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Austrian standards for nuclear medicine and X-ray

This article was originally published in Clinica

Executive Summary

The Austrian Standards Association (ON) has issued two new standards aimed at preventing harmful emissions from patients recently treated with radiation therapies from endangering the health of other people. ONORM S 5275 is aimed at providing exact details on how long patients should be quarantined after treatment and is divided into two parts, with the new regulations based on biokinetics, the location on radiation-related activity within the body and possible contamination through breathing. ONORM S 5238 will ensure the safety of implantable radioactive sources, such as seeds used in brachytherapy. It will regulate the use of these implants irrespective of whether they are temporary or permanent, said ON.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT061924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel